Seneca Growth Capital VCT plc (SVCT) B Shares
Sell:49.40p
Buy:52.50p
0
Change:
No change
No change
Market closed |
Prices as at close on 22 November 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
- Add to watchlist
- This stock can be held in a
Sell:49.40p
Buy:52.50p
Change:
No change
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Market closed |
Prices as at close on 22 November 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Sell:49.40p
Buy:52.50p
Change:
No change
No change
Market closed |
Prices as at close on 22 November 2024
Prices delayed by at least 15 minutes
|
Switch to live prices
|
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Objective
The objective of Company is to provide shareholders with an attractive income and capital return by investing its funds in a portfolio of both unquoted and AIM/NEX quoted UK companies which meet the relevant criteria under the VCT Rules. The Company will target well managed businesses with strong leadership, that can demonstrate established and proven concepts, and are seeking an injection of growth capital to support their continued development. At least the minimum required percentage of the assets of Company will be invested in Qualifying Investments as required by the VCT Rules, with the remainder held in cash and money market securities.
| Security | Weight |
|---|---|
| Solascure Limited | 7.24% |
| Pro Biotix Health Plc | 5.23% |
| Polarean Imaging Ltd ORD GBP0.00037 | 4.84% |
| Arecor Therapeutics plc ORD GBP0.01 | 4.02% |
| Fabacus Holdings Limited | 3.76% |
| Qudini Limited | 3.34% |
| Silkfred Limited | 3.34% |
| Old St Labs Limited | 3.34% |
| Aptamer Group Plc | 3.05% |
| Poolbeg Pharma Ord Shares | 2.57% |
Top 10 sectors currently unavailable.
| Country | Weight |
|---|---|
| United Kingdom | 16.22% |
Fee Structure
Annual management fee of 2% of the weighted NAV of the B share and an annual fee of GBP 9,000 in relation to management accounting services, payable quarterly in arrears. Performance fee of an amount equal to 20% of the shareholder proceeds arising.
Dividend Policy
The Company aims to maintain dividends of at least 3p per annum in relation to the Company’s B shares with an ambition to increase this to c.5% per annum of the B share NAV. This ambition remains but of course is dependent on a number of factors including investment performance and in particular the performance of the B share pool’s AIM quoted investments.
ASSET SPLIT
Trust Manager
Not currently available for this investment trust.
Manager Bio
Not currently available for this investment trust.
Board Of Directors
Ian DigheChairman, Mary Cordeiro, Richard Manley, Alex Clarkson
Data policy - All information should be used for indicative purposes only. You should
independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete,
and accepts no responsibility for how it may be used.
Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.